In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VC Playbook

Set Alert for VC Playbook

Investing Is A People Business, Says LifeArc’s Clare Terlouw

Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.

Rising Leaders VC Playbook

Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Growth Financing

VC Exec Talks M&A And 2024 Expectations

VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.

VC Playbook Deals

Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

VC Playbook Business Strategies

Investing In Digital: Slow And Steady May Win This Race

Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.

Strategy Digital Health

Biotech Cartography: Can An AI Tool Pinpoint The Next Big Thing?

Created by Steve Lehmann, director of venture operations at Portal Innovations, Stargaze is an artificial intelligence platform that maps the structure of biotechnology innovation and uses that knowledge to identify fruitful startups.

Artificial Intelligence VC Playbook

A Passion For Patient Care And De-Risking Disruptive Technologies

Biomedical engineering graduate Cécile Dupont has for the past 12 years helped healthcare technology businesses develop disruptive solutions that positively impact patients’ lives. The current chapter of her career opened in 2017 when she joined Sofinnova MD Start, the early-stage medtech incubator of VC investor Sofinnova Partners, where she is a partner.

Rising Leaders Innovation

Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments

Sofinnova Partners has played a key role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.

VC Playbook Financing

VC Playbook: Finding Early-Stage Financing When Money Is Scarce

Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.

VC Playbook Business Strategies

The New Generation Of Investor: Creating Value From Diamonds In The Rough

Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning  passion and purpose to find ultimate fulfilment.

Rising Leaders Financing

Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Financing Deals

European Investor Sentiment Rebounds On Cell And Gene Therapy

Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.

Gene Therapy Europe
See All